YUHAN CORPORATION
Financials
Valuation Metrics
YUHAN CORPORATION's Market Cap is ₩5.9T. At end of 2025 it was ₩9.1T. Ranked #90 of 2,436 in KR market (top 4%), #85 of 787 on KOSPI (top 11%), #6 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.94T KRW | KR#90/2,436 Sec#6/234 |
| Revenue | 2.22T KRW | KR#232/2,436 Sec#4/234 |
| Net Income | 198.68B KRW | KR#135/2,436 Sec#5/234 |
| Total Assets | 3.28T KRW | KR#224/2,436 Sec#6/234 |
| Net Assets | 2.34T KRW | KR#157/2,436 Sec#4/234 |
| Employees | 2,117 | KR#132/2,436 Sec#6/234 |
| Value | ||
| P/E | 29.88x | KR#1,250/2,436 Sec#75/234 |
| P/B | 2.54x | KR#2,039/2,436 Sec#158/234 |
| PEG | 0.22x | KR#552/2,436 Sec#31/234 |
| P/S | 2.67x | KR#1,969/2,436 Sec#118/234 |
| EV/EBITDA | 55.27x | KR#1,370/2,436 Sec#92/234 |
| FCF Yield | 0.11% | KR#1,209/2,436 Sec#91/234 |
| Profitability | ||
| ROE | 8.49% | KR#644/2,436 Sec#40/234 |
| ROA | 6.06% | KR#521/2,436 Sec#40/234 |
| Op. Margin | 4.81% | KR#950/2,436 Sec#75/234 |
| Revenue Growth | 7.16% | KR#1,067/2,436 Sec#98/234 |
| Earnings Growth | 133.47% | KR#344/2,436 Sec#24/234 |
| Financial Health | ||
| Debt Ratio | 40.03% | KR#142/2,436 Sec#18/234 |
| Total Debt | 354.82B KRW | KR#358/2,436 Sec#17/234 |
| FCF | 6.63B KRW | KR#829/2,436 Sec#54/234 |
| Cash | 388.91B KRW | KR#167/2,436 Sec#3/234 |
| Current Ratio | 2.03x | KR#928/2,436 Sec#108/234 |
| Net Debt/EBITDA | -0.32x | KR#619/2,436 Sec#38/234 |
| Dividend | ||
| Div. Yield | 0.82% | KR#1,191/2,436 Sec#74/234 |
| Div. Growth | 20.00% | KR#423/2,436 Sec#22/234 |
| Performance | ||
| 1Y Return | -33.57% | KR#1,662/2,436 Sec#144/234 |
| 1M Return | 6.25% | KR#406/2,436 Sec#31/234 |
| From 52W High | -42.11% | KR#855/2,436 Sec#61/234 |
| 1Y MDD | -51.10% | KR#978/2,436 Sec#81/234 |
| Trading | ||
| Volume | 216,144 shares | KR#545/2,436 Sec#54/234 |
| Foreign Own. | 19.83% | KR#226/2,436 Sec#10/234 |
| Per Share | ||
| EPS | 2,617 KRW | KR#315/2,436 Sec#21/234 |
| BPS | 30,611 KRW | KR#342/2,436 Sec#23/234 |
Company Info
Established in 1926 and listed on the securities market in 1962, the company is a leading pharmaceutical firm, with 14 companies under its umbrella, including a subsidiary slated for KOSDAQ listing in 2025. Its primary business is the manufacturing and sale of pharmaceuticals and chemical products, including key products like Leclaza. The company is building an innovative network by adopting AI and big data for new drug development, collaborating with global pharmaceutical companies, and conducting joint R&D with bio-ventures and universities. The company is headquartered in Dongjak-gu, Seoul.